Establishment and evaluation of glucose-modified nanocomposite liposomes for the treatment of cerebral malaria.

ABSTRACT: Cerebral malaria (CM) is a life-threatening neurological complication caused by Plasmodium falciparum. About 627,000 patients died of malaria in 2020. Currently, artemisinin and its derivatives are the front-line drugs used for the treatment of cerebral malaria. However, they cannot target the brain, which decreases their effectiveness. Therefore, increasing their ability to target the brain by the nano-delivery system with brain-targeted materials is of great significance for enhancing the effects of antimalarials and reducing CM mortality. This study used glucose transporter 1 (GLUT1) on the blood-brain barrier as a target for a synthesized cholesterol-undecanoic acid-glucose conjugate. The molecular dynamics simulation found that the structural fragment of glucose in the conjugate faced

SUBMITTER: Tian Y 

PROVIDER: S-EPMC9258070 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature